Treatment of MPS IIIA mice with one of these agonists (JWH133) led to a reduction of plasma and tissue CB2R and MCP‐1, a reduction of glial fibrillary acidic protein (GFAP) in the brain, and an improvement in hanging test performance. Here, GFAP is linked to mucopolysaccharidosis.